Legend Biotech (LEGN) EBITDA (2019 - 2025)

Legend Biotech (LEGN) has reported EBITDA for 7 consecutive years, with -$19.7 million the latest figure, recorded in Q4 2025.

• EBITDA for Q4 2025 came in at -$19.7 million, up 75.16% year-over-year; the trailing twelve-month figure through Dec 2025 was $82.8 million (up 335.54% YoY), and the FY2025 annual result was -$136.5 million, up 55.9% from the prior year.
• EBITDA was -$19.7 million for Q4 2025 at Legend Biotech, down from $40.6 million in the prior quarter.
• Over five years, EBITDA peaked at $45.8 billion in Q4 2023 and troughed at -$314.7 million in Q3 2022.
• Average EBITDA over 5 years is $2.3 billion, with a median of $1.7 million recorded in 2022.
• The widest YoY moves for EBITDA: up 41811.57% in 2023, down 6926.7% in 2023.
• Over 5 years, EBITDA stood at $89.8 million in 2021, then grew by 21.62% to $109.2 million in 2022, then surged by 41811.57% to $45.8 billion in 2023, then plunged by 100.17% to -$79.3 million in 2024, then soared by 75.16% to -$19.7 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$19.7 million in Q4 2025, $40.6 million in Q3 2025, and $1.2 million in Q2 2025.